Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
262 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Rank Status Study
21 Available Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
22 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
23 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
24 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
25 Approved for marketing Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sutent
26 No longer available Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
Condition: Melanoma
Intervention: Drug: Ipilimumab
27 Available EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
28 Available Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Conditions: GBM;   Glioblastoma Multiforme
Intervention: Biological: DCVax-L
29 No longer available Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
Condition: Byler Disease
Intervention: Drug: Glycerol phenylbutyrate
30 No longer available Single Patient Expanded Access Protocol: Metabolic Boost
Condition: Metachromatic Leukodystrophy
Intervention: Biological: Enriched Hematopoetic Stem Cell Transplant
31 Available Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
Condition: Cholestasis of Parenteral Nutrition
Intervention: Drug: Omegaven 10%
32 Available An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Pasireotide long acting release formulation
33 Available Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Conditions: Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System
34 Approved for marketing Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
Condition: Iron Overload
Intervention: Drug: deferiprone
35 No longer available Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
Condition: Non-small Cell Lung Cancer
Intervention: Biological: Lucanix® (belagenpumatucel-L)
36 Approved for marketing A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
Condition: Renal Transplantation
Intervention: Drug: Belatacept
37 Approved for marketing ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Condition: Mesothelioma
Interventions: Drug: Pemetrexed;   Drug: Cisplatin
38 Approved for marketing Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast Implant
Conditions: Breast Augmentation;   Breast Reconstruction;   Breast Revision
Intervention: Device: Mentor Siltex® Contour Profile Gel Mammary Prosthesis
39 No longer available Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment
Condition: Valuable Suggestions to Improve Health Care Quality Transparent and Accessible Medical Care
Intervention: Behavioral: questionnaire
40 Approved for marketing Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Idelalisib;   Drug: Rituximab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years